| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Dunn Edmund | Principal Accounting Officer | MONTE ROSA THERAPEUTICS, INC., 321 HARRISON AVENUE, SUITE 900, BOSTON | /s/ Phil Nickson, Attorney-in-Fact | 02 Mar 2026 | 0001989401 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | GLUE | Common Stock | Options Exercise | $337,449 | +25,164 | +111% | $13.41 | 47,857 | 27 Feb 2026 | Direct | |
| transaction | GLUE | Common Stock | Sale | $455,506 | -25,164 | -53% | $18.10 | 22,693 | 27 Feb 2026 | Direct | F1 |
| transaction | GLUE | Common Stock | Options Exercise | $7,188 | +536 | +2.4% | $13.41 | 23,229 | 02 Mar 2026 | Direct | |
| transaction | GLUE | Common Stock | Sale | $9,380 | -536 | -2.3% | $17.50 | 22,693 | 02 Mar 2026 | Direct |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | GLUE | Stock Option (Right to Buy) | Options Exercise | $0 | -25,164 | -98% | $0.000000 | 536 | 27 Feb 2026 | Common Stock | 25,164 | $13.41 | Direct | F2 |
| transaction | GLUE | Stock Option (Right to Buy) | Options Exercise | $0 | -536 | -100% | $0.000000 | 0 | 02 Mar 2026 | Common Stock | 536 | $13.41 | Direct | F2 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.06 to $18.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| F2 | This option is fully vested and exercisable. |